Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Dapagliflozin increases pAMPK and reduces myocardial and renal NF-kB expression in preclinical models of short-term doxorubicin cardiotoxicity through MYD-188 and NLRP3 pathways
Anno:
2023
Background: Doxorubicin-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in breast cancer patients. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to be of therapeutic value in patients with type 2 diabetes, chronic kidney disease, and heart failure with reduced ejection fraction (HFrEF),…
Leggi di più
Combination of Spirulina, Ganoderma Lucidum and Moringa Oleifera improves cardiac functions and reduces pro-inflammatory biomarkers in preclinical models of short-term doxorubicin-mediated cardiotoxicity
Anno:
2023
Background: Anthracyclines are essential adjuvant therapies for a variety of cancers, particularly breast, and gastric and esophageal cancers. Whilst prolonging cancer-related survival, these agents can in-duce drug-related cardiotoxicity. Spirulina, Reishi (Ganoderma Lucidum) and Moringa are three nutaceuticals with anti-inflammatory effects that are currently used in cancer patients to improve quality…
Leggi di più
Dapagliflozin reduces systemic PCSK9 levels in preclinical models of short-term doxorubicin cardiotoxicity through NLRP3 inflammasome/IL-1β: a first evidence of SGLT-2/PCSK9 cross-talk in cardioncology
Anno:
2023
Background: Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the development of cardiac dysfunction, arrhythmias, and clinical heart failure. In recent five…
Leggi di più
Berberine associated to Dapagliflozin exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-bloking agent Trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Anno:
2023
Background: Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction with reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i with cardio-renal benefits. In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram